-
Oct 1, 2024 | 
academic.oup.com | Hospitalet de Llobregat |María Cinta |Ma Adoración
ANCA-associated vasculitis (AAV) are chronic diseases with relapses that associate organic damage because of the disease and its treatment. Avacopan is a new treatment indicated for AAV. We present the first experiences with avacopan in Spain as part of an Early Access program. Patients with AAV who started avacopan between June 2022-September 2023 were included. For comparison, a historical cohort of patients diagnosed with AAV around the same time and treated without avacopan was also included.
-
Sep 27, 2024 | 
onlinelibrary.wiley.com | Monica Thet |John-Paul Plazzer |Gabriel Capellá |Hospitalet de Llobregat
1. Introduction Gastrointestinal (GI) polyposis syndromes are characterized by tens to thousands of polyps, of which adenomatous polyposis is the most common type. Adenomatous polyps are precancerous lesions which, if undetected, can develop into colorectal cancer (CRCs). To date, numerous types of inherited adenomatous polyps have been discovered. While each inherited form harbours adenomatous polyps, the quantity of polyps and the extracolonic manifestations can vary depending on the type.
-
Sep 9, 2024 | 
aacrjournals.org | Byoung Chul Cho |Byoung Chul |Institut Català d'Oncologia |Hospitalet de Llobregat
Background: ETOP 10-16 BOOSTER study was a randomised phase II trial of osimertinib and bevacizumab versus osimertinib in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously. Methods: Next generation sequencing (Guardant360®) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored and molecular alterations at progression were described.
-
Jun 20, 2024 | 
academic.oup.com | Precision Immuno-Oncology |Hospitalet de Llobregat
The incidence of colorectal cancer (CRC) among individuals younger than age 50 (early onset CRC; EOCRC) has substantially increased, yet the etiology and molecular mechanisms underlying this alarming rise remain unclear. We compared tumor-associated T cell repertoires between EOCRC and average-onset CRC (AOCRC) to uncover potentially unique immune microenvironment-related features by age of onset.
-
Feb 8, 2024 | 00043-6&sz=64)
cell.com | O'Byrne K |Bellvitge Hospital-IDIBELL |Hospitalet de Llobregat |Irene Fernandez-Carasa
Highlights•Rucaparib and its major metabolite M324 exhibit differential kinase selectivity•M324 displays unique PLK2 inhibition at clinically achievable concentrations•Rucaparib and M324 are synergistic in prostate cancer cell lines•M324 reduces α-synuclein accumulation in iPSC neurons from Parkinson’s patientsSummaryThe (poly)pharmacology of drug metabolites is seldom comprehensively characterized in drug discovery.
-
Nov 27, 2023 | 
onlinelibrary.wiley.com | Sandra Castaño-Díez |Helena Pomares |Institut Català d'Oncologia |Hospitalet de Llobregat
CONFLICT OF INTEREST STATEMENT J.E.: consultancy-honoraria (AbbVie, Novartis, Astellas Pharma, Jazz Pharmaceuticals, BMS-Celgene, Pfizer and Daichii-Sankyo), research grants (Novartis and Jazz Pharmaceuticals); M.D.B.: consultant or advisory role, travel grants or speaker (Bristol Myers Squibb, AbbVie, Astellas Pharma, Jazz Pharmaceuticals, Takeda Pharmaceuticals, Novartis).
-
Oct 17, 2023 | 
genomemedicine.biomedcentral.com | Hospitalet de Llobregat
Assessment of each ACMG/AMP rule code and evaluation of their utility for the classification of POLE and POLD1 ED variants was performed. Previously published specifications developed by ClinGen Variant Curation Expert Panels (VCEP) were taken into consideration (https://cspec.genome.network/cspec/ui/svi/summary), in particular those defined for cancer predisposition genes [39,40,41,42,43].
-
Sep 29, 2023 | 
cardiab.biomedcentral.com | Lipid Clinic |Universitat Ramon Llull |Palma de Mallorca |Hospitalet de Llobregat
Baseline characteristics according to baseline MEDAS scores are shown in Additional file 4, Table S1. Table 1 shows characteristics of participants classified into four categories according to the combination of their average MEDAS during the entire follow-up period (< 10 points or ≥ 10 points, averaging repeated measures from year 1 to 7, i.e., excluding baseline values) and their randomized group control or MedDiet group (both MedDiets were merged).
-
Sep 27, 2023 | 
respiratory-research.biomedcentral.com | Hospitalet de Llobregat
The datasets supporting the conclusions of this article are available in the NIH public repository Lung Tissue Research Consortium (LTRC), https://www.nhlbi.nih.gov/science/lung-tissue-research-consortium-ltrc. Tables with the full results of the analysis performed to support the conclusions are available in the online supplement. Transcriptomic data of IPF explanted lungs (n = 109) was obtained from the LTRC following established procedures.
-
Aug 25, 2023 | 
frontiersin.org | Rheumatology Unit |Hospitalet de Llobregat |de Juanes |Felipe Julio
Keywords:
biologics1, spondyloarthritis4, Combination (Combined) Therapy, Psoriatic arthritis (PsA), Inflamatory bowel disease, Safety, real word data, Multicenter study
© 2023 Valero-Martínez, Font-Urgelles, Sallés, Joven, de Juanes, Ramírez, Juanola, Almodóvar, LAIZ, Moreno, Pujol, Beltrán, Pinto-Tasende, Crespí, Sala-Icardo, Castañeda and García-Vicuña. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
